A Multicenter Phase 3 Trial of Lobeline Sulfate for Smoking Cessation
Abstract:Objective: To evaluate the safety and efficacy of sublingual lobeline sulfate for smoking cessation.
Methods: A multicenter (3 sites), double-blind, parallel, placebo-controlled, phase 3 smoking cessation trial of sublingual formulation of lobeline sulfate. A total of 750 smokers (250 per site) were randomized to either treatment (lobeline sulfate) or placebo with individual smoking cessation counseling lasting up to approximately 10 minutes.
Results: Efficacy revealed no statistical significance (P = 0.62) for lobeline sulfate as a smoking cessation aid.
Conclusion: Sublingual formulation of lobeline sulfate does not appear to be an effective smoking cessation aid.
Document Type: Research Article
Publication date: 2010-01-01
The American Journal of Health Behavior seeks to improve the quality of life through multidisciplinary health efforts in fostering a better understanding of the multidimensional nature of both individuals and social systems as they relate to health behaviors.
The Journal aims to provide a comprehensive understanding of the impact of personal attributes, personality characteristics, behavior patterns, social structure, and processes on health maintenance, health restoration, and health improvement; to disseminate knowledge of holistic, multidisciplinary approaches to designing and implementing effective health programs; and to showcase health behavior analysis skills that have been proven to affect health improvement and recovery.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Review Board
- Reprints and Permissions
- Ingenta Connect is not responsible for the content or availability of external websites